Receptor tyrosine kinases (RTKs) and their ligands have been implicated in angiogenesis and current data suggest that they are potential cancer therapeutic targets. Split-kinase domain RTKs, including receptors for vascular endothelial growth factor receptor, platelet-derived growth factor and fibroblast growth factor, have important roles in tumor angiogenesis. RTK inhibitors targeting tumor microvasculature have shown promising results in preclinical studies, and use of these compounds as single agents, or in combination with other cytotoxic therapies, including radiation, is an area of active clinical investigation. Preclinical and clinical data from representative anti-angiogenic RTK inhibitors will be discussed in this review.

Original languageEnglish
Pages (from-to)597-604
Number of pages8
JournalCurrent Opinion in Investigational Drugs
Issue number6
StatePublished - Jun 1 2004


  • Angiogenesis
  • Cancer
  • Radiation
  • Receptor tyrosine kinase
  • SU-11248
  • Vascular endothelial growth factor


Dive into the research topics of 'Receptor tyrosine kinase inhibitors as anti-angiogenic agents'. Together they form a unique fingerprint.

Cite this